A systematic review of Hepatitis B virus (HBV) drug and vaccine escape mutations in Africa

<p> </p><p>We have undertaken a systematic review of Hepatitis B virus (HBV) drug resistance associated mutations (RAMs) and vaccine escape mutations (VEMs) in Africa to quantify the prevalence, co-occurrence and geographic distribution of known mutations.</p><p><br></p><p> </p><p>Below are details of the files shared here:</p><p><br></p><p> </p><p><b>S1 Fig: </b>Flow diagram illustrating identification and inclusion of studies for a systematic review of drug and vaccine resistance mutations in Africa, based on PRISMA criteria. The search covered the time period 2007-2018. We reviewed the titles and abstracts matching the search terms (see S1 Table) and only included those relating to drug or vaccine resistance in HBV infection, including only those that presented original data and had undergone peer review.</p><p><br></p><p> </p><p><b>S2 Fig: </b>HBV drug RAMs grouped according to genotype and geographic location;</p><p><br></p><p> </p><p><b>S3 Fig: </b>Distribution of HBV genotypes and prevalence of HBV RAMs in Pol/RT proteins in geno-A and geno-non-A samples</p><p>Panel A: Distribution of HBV genotypes derived from 35 studies reporting resistance associated mutations (RAMs) in Africa published between 2009 to 2017 (inclusive);<b></b></p><p>Panel B: Prevalence of HBV resistance associated mutations (RAMs) in Pol/RT proteins in geno-A and geno-non-A samples;</p><p><br></p><p> </p><p><b>S1 Table: </b>Details of search strategy used to identify studies on HBV RAMs and VEMs conducted in Africa;</p><p><br></p><p> </p><p><b>S2 Table: </b>Full details of 37 studies identified by a systematic literature search of HBV RAMs and VEMs from African cohorts published between 2007 and 2017 (inclusive);</p><p><br></p><p> </p><p><b>S3 Table:</b> HBV Pol/RT mutations among treatment-naïve HBV infected patients in Africa from 12 studies published between 2007 and 2017 (inclusive);</p><p><br></p><p> </p><p><b>S4 Table: </b>HBV Pol/RT mutations among treatment-experienced HBV infected patients in Africa, from 25 studies published between 2009 and 2017 (inclusive);</p><p><br></p><p> </p><p><b>S5 Table: </b>First line ART regimen for adults in Africa, and overlap with HBV therapy. Information derived from published ART guidelines in all cases where these are available in the public domain.</p><p> </p>